Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (16)

2024

  1. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

    JAMA network open, Vol. 7, Núm. 4, pp. e247811

2023

  1. SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2627-2633

2018

  1. Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain

    Psycho-Oncology, Vol. 27, Núm. 6, pp. 1530-1537

2016

  1. Screening for Lynch syndrome among patients with newly diagnosed endometrial cancer: A comprehensive review

    Tumori, Vol. 102, Núm. 6, pp. 548-554

2015

  1. SEOM clinical guidelines in Hereditary Breast and ovarian cancer

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 956-961

2014

  1. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors

    Annals of Oncology, Vol. 25, Núm. 8, pp. 1656-1663

2013

  1. Analysis of PALB2 Gene in BRCA1/BRCA2 Negative Spanish Hereditary Breast/Ovarian Cancer Families with Pancreatic Cancer Cases

    PLoS ONE, Vol. 8, Núm. 7

2012

  1. Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer

    Breast Cancer Research and Treatment, Vol. 132, Núm. 1, pp. 307-315

  2. What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure?

    Breast, Vol. 21, Núm. 6, pp. 755-760

2011

  1. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry

    Breast Cancer Research and Treatment, Vol. 128, Núm. 2, pp. 573-579

  2. International distribution and age estimation of the Portuguese BRCA2 c.156-157insAlu founder mutation

    Breast Cancer Research and Treatment, Vol. 127, Núm. 3, pp. 671-679

  3. Low penetrance hereditary retinoblastoma in a family: What should we consider in the genetic counselling process and follow up?

    Familial Cancer

  4. Novel BRCA1 deleterious mutation (c.1949_1950delTA) in a woman of Senegalese descent with triple-negative early-onset breast cancer

    Oncology Letters, Vol. 2, Núm. 6, pp. 1287-1289

  5. SEOM clinical guidelines for hereditary cancer

    Clinical and Translational Oncology, Vol. 13, Núm. 8, pp. 580-586

2009

  1. Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort

    Human Reproduction, Vol. 24, Núm. 4, pp. 1000-1006

2008

  1. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain

    Clinical Cancer Research, Vol. 14, Núm. 9, pp. 2861-2869